EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
Summary
DePasqua, a medical device industry veteran who most recently led business development for the breast oncology and orthopedics units at Medtronic (NYSE: MDT), told Xconomy that EnClear will use the money to prepare for and begin human tests of its recirculation system in the first half of 2021 in patients with amyotrophic lateral sclerosis, or ALS. Next the company plans to develop a product for patients with progressive supranuclear palsy, a rare brain disorder that causes deterioration of the cells that help to control movements and thinking. That’s because the device, designed to allow access to the central nervous system, could facilitate the delivery of drugs and monitoring of biomarkers as well as filtration of harmful proteins, DePasqua says. “As the next generation of therapeutics comes out, like [antisense oligonucleotides] and gene therapies, they all have intrathecal [drug] delivery [systems], they all have different requirements from where they need to go, when they need to go, the amount that needs to get into the body past the blood-brain barrier,” he said. “With access to the central nervous system and CSF, we can help deliver those therapies in a meaningful way, and that’s what we’re testing out and developing strategic partnerships around at this point.” EnClear, currently a team of three, anticipates adding four more full-time employees this year, DePasqua says.
Classifications
AskAI Classifications
LabelsLinked Companies
